A multicentre, long-term trial of KN01 in patients with MELAS

A multicentre, long-term trial of KN01 in patients with MELAS - Long-term taurine-MELAS study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019195

Enrollment

Registered

2015-10-08

Start date

2015-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MELAS

Interventions

taurine supplementation: (1)duration:104 wks (2)dose: 12 g (BW&gt

40 kg), 9 g (BW:25-40 kg), 6 g (BW:15-25 kg), 3 g (BW&lt

15 kg) (3)times: TID (4)frequency: daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients agreed with the long-term taurine supplementation study, who priorly participated in the short -term one (UMIN000011908) .

Exclusion criteria

Exclusion criteria: Same as the prior short-term study.

Design outcomes

Primary

Measure	Time frame
(1)efficiency:annual relapsing rates of stroke-like episodes. (2)safety:adverse events and advise effects	—

Countries

Japan

Contacts

Public ContactMai Moriyama

CTD inc. Medical Prodiucts Promotion Division

taurine@c-ctd.co.jp03-6228-4105

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026